期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

非小细胞肺癌VEGF-C的表达及LYVE-1标记的微血管密度与淋巴结转移的关系 被引量：4

下载PDF
导出
摘要 目的探讨非小细胞肺癌(NSCLC)血管内皮生长因子(VEGF)-C的表达与内皮透明质酸受体-1(LYVE-1)标记的微淋巴管密度(MLVD)与淋巴结转移的关系及意义。方法采用免疫组织化学染色法检测56例NSCLC、10例肺良性病变组织中VEGF-C的表达水平,采用淋巴管特异性标志物LYVE-1检测MLVD,并做相关统计学分析。结果 VEGF-C蛋白在NSCLC组织中的阳性率明显高于肺良性病变组织(P<0.05)。NSCLC组织中LYVE-1标记的MLVD明显高于肺良性病变组织(P<0.05)。VEGF-C表达阳性的组织中MLVD显著高于阴性组织(P<0.05)。VEGF-C蛋白的表达与NSCLC患者淋巴结转移、PTNM分期有关。结论淋巴管生成因子VEGF-C在NSCLC中表达明显升高,其促进了淋巴血管内皮细胞的大量增殖以及淋巴血管的生成,对肿瘤生长和转移起到了促进作用。
作者 刘东华
机构地区 内蒙古医科大学附属医院保健中心
出处 《中国老年学杂志》 CAS CSCD 北大核心 2012年第18期3927-3928,共2页 Chinese Journal of Gerontology
关键词 血管内皮生长因子C 淋巴管内皮透明质酸受体-1 非小细胞肺癌 淋巴转移
分类号 R734 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Mattern J,Koommagl R,Voim M.Biological characterization of subgroups of squamous cell lung carcinomas[J].Clin Cancer Res,1999;5(6):1459-63.
  • 2郑亚民,达明绪,赵紫罡,张明鸣,罗婷,伍晓汀.胃癌癌周微淋巴管密度与肿瘤侵袭转移的相关性研究[J].华西医学,2006,21(2):269-271. 被引量：13
  • 3Hirakawa S,Brown LF,Kodama S,et al.VEGF-C induced lymphangio-genesis in sentinel lymph nodes promotes tumor metastasis to distant sites[J].Blood,2007;109(3):1010-7.
  • 4Karkkainen MJ,Haiko P,Sainio K,et al.Vascular endothelial growth fac-tor C is required for sprouting of the first lymphatic vessels from embryon-ic veins[J].Nat Immunol,2004;5(1):74-80.
  • 5Yonemura Y,Endo Y,Tabata K,et al.Role of VEGF-C and VEGF-D in lymphangiogenesis in gastric cancer[J].Int J Clin Oncol,2005;10(5):318-27.
  • 6Vainionpaa N,Biitzow R,Hukkanen M,et al.Basement membrane protein distribution in LYVE-1 immunorcactive lymphatic vessels of normaltissues and ovarian carcinomas[J].Cell Tissue Res,2007;328(2):317-28.
  • 7汪源,潘铁成,陈涛.非小细胞肺癌(NSCLC)的LYVE-1阳性微淋巴管密度与肿瘤淋巴转移的关系[J].现代肿瘤医学,2009,17(7):1243-1245. 被引量：3

二级参考文献32

  • 1王天宝,董文广,韩方海,李兆亭.血管内皮生长因子受体-3与胃癌临床病理因素的关系[J].中国普外基础与临床杂志,2004,11(4):341-343. 被引量：5
  • 2Fu XL, Zhu XZ, Shi DR, et al. Study of prognostic predictors for non small cell lung cancer [ J]. Lung Cancer, 1999,23 (2) :143 - 152.
  • 3Gasparini G, Harris A. Clinical importance of the determination of tumor angiogenesis in breast carcinima: much more than a new prognostic tool [ J ]. J Clin Oncol, 1995,13 (3) :765 - 782.
  • 4Jackson DG, Prevo R, Clasper S, et al. LYVE - 1, the lymphatic system and tumor lymphangiogenesis [ J]. Trends Immunol, 2001, 22(6) :317 -321.
  • 5Banerji S,Ni J,Wang SX,et al. LYVE - 1 ,a new homologue of the CD44 glycoprotein,is a lymph specific receptor for hyaluronan [ J ]. J Cell Biol, 1999,144:789 - 801.
  • 6Kim H, Dumont DJ. Molecular mechanisms in lymphangiogenesis: model systems and implications in human disease [ J]. Clin Genet, 2003,64(4) :282 -292.
  • 7Scavelli C, Weber E, Agliano M, et al. Lymphatics at the crossroads of angiogenesis and lymphangiogenesis [ J]. J Anat,2004,204 (6) : 433 - 449.
  • 8Farnsworth RH, Achen MG, Stacker SA. Lymphatic endothelium : an important interactive surface for malignant cells[ J]. Pulm Pharmacol Ther,2006,19( 1 ) :51 -60.
  • 9Terhi Karpanen, Karl Alitalo. Lymphatic vessels as targets of tumor therapy[ J]. Exp Med ,2006,194 (6) : F37 - F42.
  • 10Enholm B,Jussila L,Karkkainen M,et al.Vascular endothelial growth factor-C:a growth factor for lymphatic and blood vascularendothelial cells[J].Trends Cardiovasc Med,1998,8(7)∶292-295.

共引文献14

同被引文献49

  • 1杨润祥,刘林,马飞,钱海利,杨芳.甲状腺癌中CCR7和D2-40的表达及其与淋巴结转移的关系[J].肿瘤防治研究,2014,41(5):418-422. 被引量：5
  • 2廖系晗,金翠兰.茶多酚及其抗癌机理的研究进展[J].时珍国医国药,2006,17(9):1783-1785. 被引量：30
  • 3Langer C J, Natale R B. The emerging role of vascularendothelial growth factor receptor tyro-sine kinaseinhibitors [J]. Semin Oncol, 2009,32(10): 23-29.
  • 4Faulkner K, Mithen R, Williamson G. Selective increaseof thepotential anticarcinogen 4-methyIsuIphinylbutylglucosinolate inbroccoli [J]. Carcinogenesis, 2011,19(4):605-609.
  • 5Kadish A S,Doyle A T, Steinhauer E H,et aL Naturalcytotoxic-ity and interferon production in human cancer:Deficient inaturalkiller activity and normal interferonproduction in patients with advanced disease [J]. J Immunol,2010, 127(2): 1817-1822.
  • 6Ishii H, Mimori K, Yoshikawa Y,et al. Differential rolesof E-type cyclins during transformation of murine E2F-1deficientcells [J]. DNA Cell Biol, 2011, 24(3): 173-179.
  • 7Yamadai S,Sumrejkanchanakij P,Amagasa T,et al. Lossofcyclin E requiement in cell growth of an oral squamouscellcarcinoma cell line implies deregulation of its down-streampathway [J]. Int J Cancer, 2009, 111(1): 17-22.
  • 8Kim K I,Cho H J, Hahn J Y,et al Beta-cateninoverexpressionaugments angiogenesis and skeletal muscleregenerationthrough dual mechanism of vascular endothelialgrowth factor-mediated endothelial cell proliferationandprogenitor cellmobilization [J]. Arterioscler Thromb VaseBiol, 2010,26(1):91-98.
  • 9Zariwala M, Liu J, Xiong Y. Cyclin E2, a novel humanGlcyclin and activating partner of CDK2 and CDK3, isinduced byviral oncoproteins [J]. Oncogene, 2011,17(21):2787-2798.
  • 10Coghlan V M, Langeberg L K, Fernandez A, et al.Cloning and characterization of AKAP 95,a nuclearprotein that associates with the regulatory subunit of typeII cAMP-dependent protein kinase [J]. J Biol Chem, 2012,26(9): 7658-7660.

二级引证文献19

中国老年学杂志
2012年 第18期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部